HORIZON-PFT: Pivotal Fracture Trial
- Conditions
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7700
- Registration Number
- NCT00049829
- Locations
- ๐บ๐ธ
Palm Beach Research Center, West Palm Beach, Florida, United States
๐บ๐ธBrigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
- Conditions
- First Posted Date
- 2002-10-04
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 484
- Registration Number
- NCT00046748
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
- Conditions
- First Posted Date
- 2002-09-25
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2127
- Registration Number
- NCT00046254
- Locations
- ๐ฉ๐ช
Novartis, Nuernberg, Germany
๐บ๐ธRadiant Research Lake Worth, Lake Worth, Florida, United States
๐บ๐ธUniversity of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
- Conditions
- Interventions
- First Posted Date
- 2002-09-18
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 144
- Registration Number
- NCT00045942
- Locations
- ๐บ๐ธ
UCLA Medical Center, Los Angeles, California, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis
- Conditions
- First Posted Date
- 2002-05-10
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00036413
- Locations
- ๐บ๐ธ
Neurological Institute, New York, New York, United States
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
- Conditions
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 261
- Registration Number
- NCT00035997
- Locations
- ๐บ๐ธ
Urology Associates of Central CA, Fresno, California, United States
๐บ๐ธAdvanced Urology Medical Office, Los Angeles, California, United States
๐บ๐ธSouthwest Florida Urologic Association, Fort Myers, Florida, United States
EPO906 Therapy in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT00035087
- Locations
- ๐บ๐ธ
Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
EPO906 Therapy in Patients With Advanced Melanoma
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT00035165
- Locations
- ๐บ๐ธ
Comprehensive Cancer Center@ Our Lady if Mercy Medical Center, Bronx, New York, United States
๐บ๐ธUniversity of Colorado, Aurora, Colorado, United States
๐บ๐ธH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
EPO906 Therapy in Patients With Advanced Kidney Cancer
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT00035243
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
๐ซ๐ทCentre L. Berard, Lyon, France
๐บ๐ธUCLA Medical Center, Los Angeles, California, United States
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT00035100
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Surrey, United Kingdom